Bio-Rad Laboratories, Inc. (BIO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Devices) last closed at $369.14. The rating moved from Neutral to Oversold on October 2, 2026.

• Public ratingOversold (as of October 3, 2026)
• Last close$369.14
• Last changeMoved from Neutral to Oversold on October 2, 2026
• SectorHealthcare
• IndustryMedical Devices

See all oversold Healthcare stocks →

AI analysis

Bio-Rad Laboratories, Inc. (BIO) combines a durable consumables franchise with recurring revenue from an extensive installed base across life-science research and clinical diagnostics. That structural revenue mix supports margin resilience and cash generation, while new molecular and specialty diagnostic assays offer tangible medium-term upside. Near-term performance will be sensitive to macro-driven capital spending patterns, supply-chain timing and reimbursement dynamics. The current risk-off market tone may limit near-term upside, but the company’s technical positioning, diversified end markets and potential for selective M&A provide a favorable multi-quarter growth runway under a base-case scenario.

Key factors

• Recurring consumables and reagent revenue from a large installed base provides gross margin stability and predictable cash flow.
• Diversified business mix across Life Science Research and Clinical Diagnostics reduces single-market exposure.
• Strong brand and technical support create high switching costs for many diagnostic and laboratory customers.
• Growth opportunities from molecular and specialized diagnostic assays, as well as expansion into clinical testing workflows.
• Resilient demand for diagnostic reagents and replacement parts even in risk-off environments, partially insulating revenue.
• Prudent balance-sheet positioning historically enables selective M&A and product investment to sustain long-term growth.

Risks

• Near-term macro and risk-off market sentiment can delay capital equipment purchases by labs and hospitals, pressuring instrument sales.
• Ongoing global supply chain disruptions could delay instrument deliveries and increase component costs, compressing margins.
• Reimbursement pressures or policy actions (e.g., Medicare negotiation dynamics) that constrain pricing or access for certain diagnostics.
• Intense competition from other life‑science tools and diagnostics vendors and rapid technological change could erode market share.
• Regulatory hurdles for new assays or diagnostic platforms could slow commercialization and revenue recognition.
• Foreign-exchange and geopolitical risks given material international revenue exposure.

Latest MarketMoodz coverage

• Elliott Sees Billions Hidden Inside Bio‑Rad Laboratories2026-05-18

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.